Vir Biotechnology
197 hedge funds and large institutions have $656M invested in Vir Biotechnology in 2024 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 77 increasing their positions, 68 reducing their positions, and 38 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 68
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.56% less ownership
Funds ownership: 64.67% → 64.11% (-0.56%)
8% less funds holding
Funds holding: 215 → 197 (-18)
16% less capital invested
Capital invested by funds: $783M → $656M (-$127M)
45% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 38
86% less call options, than puts
Call options by funds: $1.28M | Put options by funds: $8.95M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$10.9M |
| 2 |
JFG
Jefferies Financial Group
New York
|
+$9.43M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.99M |
| 4 |
State Street
Boston,
Massachusetts
|
+$4.61M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$2.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$13.4M |
| 2 |
Morgan Stanley
New York
|
-$7.7M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$4.47M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$4.18M |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$3.99M |
VIR Hedge Fund Activity: Q3 2024 in Review
197 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q3 2024, worth a combined $656M — down 16% from $783M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of VIR and 21 opened new positions — a net loss of 17 holders — while 68 trimmed existing stakes and 77 added.
The largest buyer was OrbiMed, adding an estimated $10.9M. The largest seller was Baillie Gifford & Co, cutting an estimated $13.4M.
- 197 institutional investors held Vir Biotechnology (VIR) as of Q3 2024, down from 215 in Q2 2024.
- Funds reported $656M of Vir Biotechnology stock for Q3 2024, down 16% quarter-over-quarter.
- 21 funds opened new Vir Biotechnology positions in Q3 2024 and 38 closed out, a net change of -17 holders.
- The largest Vir Biotechnology buyer in Q3 2024 was OrbiMed, an estimated $10.9M added.
- The largest Vir Biotechnology seller in Q3 2024 was Baillie Gifford & Co, an estimated $13.4M sold.
Based on aggregated 13F filings for Q3 2024.